Disease-activity-free status in patients with relapsing–remitting multiple sclerosis treated with daclizumab high-yield process in the SELECT study

Freedom from disease activity in multiple sclerosis

(2015) E. Havrdova et al.   NEUROLOGY

Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial

(2013) Ralf Gold et al.   LANCET

New treatments and treatment goals for patients with relapsing-remitting multiple sclerosis

(2012) Edward J. Fox et al.   CURRENT OPINION IN NEUROLOGY

Disability outcome measures in multiple sclerosis clinical trials: current status and future prospects

(2012) Jeffrey A Cohen et al.   LANCET NEUROLOGY

Teriflunomide Increases the Proportion of Patients Free from Disease Activity in the TEMSO Phase III Study (PD5.007)

(2012) M. Freedman et al.   NEUROLOGY

Anti-CD25 (daclizumab) monoclonal antibody therapy in relapsing–remitting multiple sclerosis

(2011) Roland Martin   CLINICAL IMMUNOLOGY

Multiple Sclerosis: Pathogenesis and Treatment

(2011) Ingrid Loma et al.   Current Neuropharmacology

Acute myocardial infarction and heart failure in acute stroke patients: frequency and influence on clinical outcome

(2011) Sara Micheli et al.   JOURNAL OF NEUROLOGY

Alemtuzumab versus interferon beta-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes

(2011) Alasdair J Coles et al.   LANCET NEUROLOGY

Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis

(2011) Gavin Giovannoni et al.   LANCET NEUROLOGY

Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta

(2010) Daniel Wynn et al.   LANCET NEUROLOGY

A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis

(2010) Gavin Giovannoni et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mechanisms of neuronal dysfunction and degeneration in multiple sclerosis

(2010) Ranjan Dutta et al.   PROGRESS IN NEUROBIOLOGY

Corticosteroids and plasma exchange in multiple sclerosis

(2009) Hayretin Tumani   JOURNAL OF NEUROLOGY

Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study

(2009) Eva Havrdova et al.   LANCET NEUROLOGY

Multiple Sclerosis: An Immune or Neurodegenerative Disorder?

(2008) Bruce D. Trapp et al.   Annual Review of Neuroscience